SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Dec 6, 2018
TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Dec. 6, 2018 · CIK: 0000034956 · Accession: 0001654954-18-013650
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228212
Letter
Blueprint
Ladenburg Thalmann & Co. Inc.
Vanderbilt Beach Road, Suite 200
Naples, Florida 34108
December 6, 2018
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Re:
TENAX THERAPEUTICS, INC.
Registration Statement on Form S-1 (Registration No. 333-228212)
Withdrawal of Concurrence in Acceleration Request
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on December 4, 2018, in which Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the above-referenced offering, concurred in the request by Tenax Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on December 6, 2018, pursuant to Rule 461 under the Securities Act. Tenax Therapeutics, Inc. is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Very
truly yours,
LADENBURG
THALMANN & CO. INC.
Show Raw Text
CORRESP 1 filename1.htm Blueprint Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34108 December 6, 2018 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: TENAX THERAPEUTICS, INC. Registration Statement on Form S-1 (Registration No. 333-228212) Withdrawal of Concurrence in Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on December 4, 2018, in which Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the above-referenced offering, concurred in the request by Tenax Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on December 6, 2018, pursuant to Rule 461 under the Securities Act. Tenax Therapeutics, Inc. is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date. Very truly yours, LADENBURG THALMANN & CO. INC. By: /s/ Nicholas Stergis Name: Nicholas Stergis Title: Managing Director